Accenture Announces Collaboration with Bayer to Streamline Drug Development Processes through INTIENT Clinical Platform
NEW YORK; Sept. 16, 2019 – Accenture (NYSE: ACN) has announced a collaboration with Bayer to implement the Accenture INTIENT Clinical platform to help simplify and speed its drug development processes. The platform, which went live at Bayer earlier this year, brings internal and external clinical data together with Oracle cloud-based technologies into a single data management and warehousing platform, creating actionable insights to accelerate drug development and improve patient outcomes.
from News | Accenture Newsroom https://ift.tt/2UVuKo1
from News | Accenture Newsroom https://ift.tt/2UVuKo1
Comments
Post a Comment